Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$575.98 ▲ +13.07
(+2.32%)
MKT CAP: $45.38B • VOL: 479.5K
52W L $501 52W H $770
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$484
MEDIAN
$645
MEAN
$657
HIGH
$783
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE IDXX TAPE
IDXX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $696.94 | $662.38 | 2025-02-14 | $524.14 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $725.73 | $679.66 | 2025-02-06 | $541.42 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $656.62 | $633.58 | 2025-01-29 | $552.94 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $587.50 | — | 2025-01-17 | $564.46 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $506.86 | $547.18 | 2025-01-09 | $512.62 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $685.42 | $599.02 | 2024-12-18 | $501.10 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $558.70 | $581.74 | 2024-12-04 | $535.66 | -4.3% | 48% | C |